Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × mirdametinib × Clear all

Phase

Phase 1/2 2 Phase 1 2 Phase 2 1

Status

Recruiting 2 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 1 Neurofibroma 1

Interventions

Cyclophosphamide 629 Cisplatin 592 Gemcitabine 558 Bevacizumab 536 Carboplatin 525 Paclitaxel 520 Docetaxel 499 Radiotherapy 484 Fluorouracil 362 Oxaliplatin 342 Rituximab 327 Capecitabine 312 Doxorubicin 308 Etoposide 286 Filgrastim 284 Irinotecan 276 Dexamethasone 272 Leucovorin 249 Cetuximab 229 pembrolizumab 225 Cytarabine 205 Bortezomib 198 Trastuzumab 193 Erlotinib Hydrochloride 191 Prednisone 188 Vincristine 187 Nivolumab 186 Pemetrexed 176 fludarabine phosphate 169 Temozolomide 169

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡